Physician profile
Mark F Hebert
NPI 1801884812
$1,131.88
in general payments reported to CMS, 2019-2025
15 companies · $23.97 in 2025
The $23.97 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $115 · 2021: $67.37 · 2022: $201 · 2023: $309 · 2024: $236 · 2025: $23.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.06 |
| Education | $149.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $179.84 | 2024 | |
| Bard Peripheral Vascular, INC. | $176.17 | 2020-2023 | Lutonix Drug Coated Balloon |
| Imperative Care, INC | $144.64 | 2023 | Prodigy Catheter |
| Abbvie INC. | $110.56 | 2023-2024 | |
| Davol INC. | $109.85 | 2019-2025 | Phasix Mesh |
| Emd Serono, INC. | $86.55 | 2019-2020 | |
| Medtronic, INC. | $70.23 | 2022-2023 | Chameleon |
| Smith+Nephew, INC. | $69.42 | 2019-2023 | Regranex, Collagenase Santyl, Iodosorb Ointment 40g USA |
| Pacira Pharmaceuticals Incorporated | $51.18 | 2019-2023 | Exparel |
| Organogenesis INC. | $43.04 | 2022 | |
| Myriad Genetic Laboratories, INC. | $23.89 | 2022 | |
| Kci USA, INC. | $18.94 | 2022 | |
| Innocoll Pharmaceuticals Limited | $18.88 | 2022 | |
| Polynovo North America LLC | $14.66 | 2024 | Novosorb Btm |
| Acacia Pharma INC | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.